Innovotech Inc. (TSXV:IOT)
Canada
· Delayed Price · Currency is CAD | Market Cap | 11.30M |
| Revenue (ttm) | 4.53M |
| Net Income (ttm) | 94.38K |
| Shares Out | 54.44M |
| EPS (ttm) | 0.00 |
| PE Ratio | 111.62 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 41,863 |
| Open | 0.220 |
| Previous Close | 0.208 |
| Day's Range | 0.220 - 0.220 |
| 52-Week Range | 0.140 - 0.340 |
| Beta | 1.17 |
| RSI | 52.34 |
| Earnings Date | Aug 21, 2026 |
About Innovotech
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assay lids; and order biofilm assays. It also provides antimicrobial contract research and antimicrobial testing; antimicrobial and anti-biofilm agents; an... [Read more]
Financial Performance
In 2025, Innovotech's revenue was 4.53 million, an increase of 106.65% compared to the previous year's 2.19 million. Earnings were 94,375, a decrease of -58.01%.
Financial StatementsNews
Innovotech Inc. Begins Trading on OTCQB Under Symbol IOTCF, Expanding Access for U.S. Investors
Edmonton, Alberta – April 14, 2026 - TheNewswire – Innovotech Inc. ( TSXV: IOT , OTCQB: IOTCF) (“Innovotech” or the “Company”), a diversified life sciences technology company specializing in applied ...
Innovotech (IOT:CA) Launches $200,000 Convertible Debenture Offering
Innovotech (IOT:CA) Launches $200,000 Convertible Debenture Offering